Graft-versus-tumour effect in refractory metastatic neuroblastoma [4]

Bone Marrow Transplantation

Volumn 39, Issue 12, 2007, Pages 809-810

  Marabelle, A ^a,b   Paillard, C ^a,b   Tchirkov, A ^a,c   Halle, P ^a,b   Chassagne, J ^c   Demeocq F ^a,b   Kanold, J ^a,b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INSERM   (France)

^c CENTRE JEAN PERRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; ISOTRETINOIN; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TEMOZOLOMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CASE REPORT; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; METASTASIS POTENTIAL; MINIMAL RESIDUAL DISEASE; MONOSOMY 7; NEUROBLASTOMA; PRIORITY JOURNAL; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; SCHOOL CHILD; WHOLE BODY RADIATION;

ACUTE DISEASE; BONE MARROW TRANSPLANTATION; BONE NEOPLASMS; CHILD; FEMALE; GRAFT VS TUMOR EFFECT; HUMANS; LEUKEMIA, MYELOID; NEUROBLASTOMA;

EID: 34250164296     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705681     Document Type: Letter

References (7)

1. Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J et al. Harnessing graft-versus-malignancy: Nonmyeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18-29.
2. Childs R, Chernoff A, Contentin N, Bahceci E, Schrump D, Leitman S et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000; 343: 750-758.
3. Kanda Y, Komatsu Y, Akahane M, Kojima S, Asano-Mori Y, Tada M et al. Graft-versus-tumor effect against advanced pancreatic cancer after allogeneic reduced-intensity stem cell transplantation. Transplantation 2005; 79: 821-827.
4. Tchirkov A, Kanold J, Combaret V, Philip I, Kwiatkowski F, Malet P et al. Immunological and molecular detection of tumor contamination in leukapheresis products from children with disseminated neuroblastoma: implication for evaluation of tumor cell depletion after CD34 selection. Bone Marrow Transplant 1999; 24: 229-230.
5. Reynolds CP. Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr Transplant 2004; 8 (Suppl 5): 56-66.
6. Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML. Ann Hematol 1999; 78: 418-425.
7. Fleischhack G, Hasan C, Graf N, Mann G, Bode U. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: Experiences of a phase II trial. Br J Haematol 1998; 102: 647-655.